Supplementary Table 8. Categorization of Salvage Regimens from Overall 36 Randomized Controlled Trials with 77 Intervention Arms

Category	Previous failed regimen		Interventions, n (number of intervention arms)
2nd line, 23 studies, 47 arms	PAC fail, 15 studies, 31 arms	Bismuth quadruple, n=12	PBTM, n=9[a]
			PBTA, n=2
			PBMA, n=2
		Quinolone triple, n=9	PAL, n=8[a]
			PML, n=1
		Quinolone quadruple, n=5	Levo-bismuth+AMX (PBLA), n=2
			Levo-bismuth+tetra (PBLT), n=1
			Levo-sequential (PA-PML), n=2
		Others, n=4	PAM, n=2
			PAT, n=1
			PATM, n=1
			Concomitant (PACM), n=1
	PAM fail, 1 study, 2 arms		PB+furazolidone+levofloxacin, n = 1
			PB+furazolidone+rlufoxacin, n=1
	PAC/M fail, 2 studies, 4 arms		Levo-bismuth (PBLA), n=1
			PBTM, n=1
			Furazolidone+PL, n=1
			Furazolidone+PB+doxycycline, n=1
	Triple, n-s, 2 studies, 4 arms		Sequential (PA-PC+tinidazole), n=1
			PBTM (tetracycline/doxycyline), n=1
			PBTM, n=1
			PM+moxifloxacin, n=1
	PBAC/M, 2 studies, 4 arms		Quintuple: PBTM+oxfloxacin, n=1
			Quintuple: PBAC+tinidazole, n=1
			PBAC, n=1
			PB+ofloxacin+azithromycin, n=1
	N-S, 2 studies, 5 arms		PAL, n=2
			Levo-sequential (PA-PML), n=1
			High dose dual (PA), n=1
			Sequential (PA-PCM), n=1
3rd line, 5 studies, 11 arms	PAC-PAM fail, 3 studies, 7 arms	Quinolone triple, n=5	PA+sitafloxacin, n=2
			PM+sitafloxacin, n=1
			PAL, n=1
			PA+gatifloxacin, n=1
		Dual (not high dose), n=2	PA, n=2
	PACM+quinolone fail, 2 studies, 4 arms		PBTM, n=1
			PBMA, n=1
			PB+minocycline+tinidazole, n=1
			PB+minocycline+rifabutin, n=1
Duration, 5 studies, 12 arms	PAC fail, 3 studies		PBTM, 7d vs. 14d, 3 studies[a]
	PAC/M fail, 1 study		PAL, 7d vs. 10d, 1 study (levofloxacin 500 mg vs. 1,000 mg)
	PAC-PAM (-sitafloxacin regimen) fail, 1 study		PA+rifabutin, 10d vs. 14d, 1 study
PPI comparison, 2 studies, 4 arms	PAC-PBTM fail, 1 study		Rifabutin+amoxicillin 1g tid+PPI standard vs. double dose bid, 1 study
	PAC fail, 1 study		PBTM: rabeprazole vs. esomeprazole, 1 study

P, proton pump inhibitor; A, amoxicillin; C, clarithromycin; B, bismuth; T, tetracycline; M, metronidazole; L, levofloxacin; n-s, not significant; PPI, proton pump inhibitor.
[a]Included in the meta-analysis.